Metrics of clonidine utilization in maintenance hemodialysis patients

Sarita M., Praveen Kumar K., Rama Mohan P.


Background: Clonidine is less frequently used by nephrologists. Data on clonidine prescribing trends in hemodialysis patients is sparse. We assessed the clonidine utilization metrics from the case records of patients undergoing maintenance hemodialysis.

Methods: In this retrospective chart review, we analysed the clinical records of hemodialysis patients using clonidine. We evaluated the frequency of clonidine use, mean dose of clonidine and percentage of patients receiving a particular dose. Additionally, we also correlated dose of clonidine with anti-hypertensive pill count.

Results: A total of 70 hemodialysis patients case records were screened. All 70/70 (100%) of them were hypertensive. Only 25/70 (35.74%) of patients were prescribed clonidine as an anti-hypertensive agent. The mean clonidine dose was 352±171 µg. Majority of patients 9/25 (36%) received 400 µg of clonidine. The dose of clonidine was prescribed in the order 400 µg (36%)>200 µg (32%)>600 µg (16%)>100 µg (8%)>300 µg (4%)=700 µg (4%). There was a statistically significant correlation in the strength of clonidine prescribed with increasing anti-hypertensive drugs (p<0.05).

Conclusions: In our study, we observed that 80% of our hemodialysis patients were non responders to either systolic blood pressure or diastolic blood pressure or both. Oral clonidine use was observed in 35.74% of our hemodialysis patients. There was a linear trend showing an increased dose of clonidine with an increase in the anti-hypertensive pill count.


Anti-hypertensive pill count, Blood pressure response, Clonidine strength, Correlation, Dose

Full Text:



Agarwal R, Nissenson AR, Batlle D, Coyne DW, Trout JR, Warnock DG. Prevalence, treatment, and control of hypertension in chronic hemodialysis patients in the United States. Am J Med. 2003 Sep;115(4):291-7.

Horl MP, Horl WH. Drug therapy for hypertension in hemodialysis patients. Seminars in dialysis. 2004 Jul-Aug;17(4):288-94.

Reis DJ, Piletz JE. The imidazoline receptor in control of blood pressure by clonidine and allied drugs. Am J Physiol. 1997;273(5):R1569-R71.

Wijeysundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. The Am J Med. 2003 Jun 15;114(9):742-52.

Inrig JK. Antihypertensive agents in hemodialysis patients: a current perspective. Semin Dial. 2010 May-Jun;23(3):290-7.

Aronow WS. Treatment of systemic hypertension. Am J Cardiovasc Dis. 2012;2(3):160-70.

Turner JM, Peixoto AJ. Blood pressure targets for hemodialysis patients. Kidney Int. 2017 Oct;92(4):816-823.

Izzo JL, Jr., Santarosa RP, Larrabee PS, Smith RJ, Kallay MC. Increased plasma norepinephrine and sympathetic nervous activity in essential hypertensive and uremic humans: effects of clonidine. J Cardiovasc Pharmacol. 1987;10(Suppl 12):S225-9.

Schlicker E, Feuerstein T. Human presynaptic receptors. Pharmacol Therapeutics. 2017 Apr;172:1-21.

Georgianos PI, Agarwal R. Pharmacotherapy of Hypertension in Chronic Dialysis Patients. Clin J Am Soc Nephrol. 2016 Nov 7;11(11):2062-75.

Gregorakos L, Thomaides T, Stratouli S, Sakayanni E. The use of clonidine in the management of autonomic overactivity in neuroleptic malignant syndrome. Clin Auton Res. 2000 Aug;10(4):193-6.

Shibao C, Gamboa A, Abraham R, Raj SR, Diedrich A, Black B, Robertson D, Biaggioni I. Clonidine for the treatment of supine hypertension and pressure natriuresis in autonomic failure. Hypertension. 2006 Mar;47(3):522-6.

Ahmad R, Habib A, Rehman S. Efficacy of various antihypertensive drugs in the treatment of hypertension in the patients of end-stage renal disease leading to hemodialysis: a retrospective study. Int J Adv Med. 2017;4:203-8.

Ribeiro H, Pereira S, Dias VP, Fernandes JC. PP.25.01: Clonidine the current effectiveness of an old drug in patients with chronic kidney disease. J Hypertension. 2015;33:e351.

Neil MJ. Clonidine: clinical pharmacology and therapeutic use in pain management. Current Clinical Pharmacol. 2011;6(4):280-7.